Jemperli (Dostarlimab): First Immunotherapy for Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer Product Name: Jemperli Active Ingredients: Dostarlimab Major Class: Checkpoint Inhibitor Minor Class: PD-1 Dose Forms: Solution for infusion (concentrate) Strength: 500 mg/10 mL Containers: Vial Pack Sizes: One Routes of Administration: Intravenous Pregnancy category: D Other Ingredients: Sodium citrate dihydrate, arginine hydrochloride, citric acid monohydrate, sodium chloride, polysorbate 80 and water for injection
About Jemperli (Dostarlimab) Jemperli (chemical name: dostarlimab-gxly) is approved by the U.S. Food and Drug Administration (FDA) in order to treat dMMR endometrial cancer where the cancer is advanced or has returned back, and has got worse despite the treatment with platinum-containing chemotherapy. Endometrial cancer is a kind of cancer that occurs in the lining of the womb (the endometrium). When this cancer is advanced, it has progressed outside the womb to neighboring organs (such as the ovaries), or to organs further far in the body. Jemperli is for patients where the cancer is MSI-H or dMMR (these genetic changes can be recognized by a test using a biopsy). At present scenario treatment options for these patients are limited. This medicinal product is typically supplied as 500 mg/10 mL dosage strength.
Note: Jemperli (dostarlimab-gxly 500 mg) also used for solid tumors, as determined by an FDAapproved test, that have progressed on or following previous treatment and who have no satisfactory alternative treatment options. Limitations of Use Age: The safety as well as efficacy of Jemperli in patients aged under 18 years have not been established. Fertility/Pregnancy/Breastfeeding: Jemperli treatment can be responsible for causing harm to a fetus and its use is not recommended during pregnancy. Pregnancy needs to be prevented during therapy with Jemperli and for at least 4-months after the final dose of this medicine. The risks associated with this medication during breastfeeding are not specified and cannot be ruled out. Due to the potential for severe side effects in the breastfed child, women should not breastfeed during treatment and for at least 4-months after the final dose of jemperli 500 mg. Complications of stem cell transplant: Life-threatening and severe transplant-related complications can emerge in such patients who receive a stem cell transplant from a donor prior to or after being treated with this medicine. How Does Jemperli (Dostarlimab) Work